CFTR Potentiator PG-01 and Corrector KM-11060 can rescue hERG mutations trafficking by Zhang, J. et al.
 The University of Bradford Institutional 
Repository 
http://bradscholars.brad.ac.uk 
This work is made available online in accordance with publisher policies. Please refer to the 
repository record for this item and our Policy Document available from the repository home 
page for further information. 
To see the final version of this work please visit the publisher’s website. Available access to 
the published online version may require a subscription. 
Link to publisher’s version: 
http://www.physoc.org/proceedings/abstract/Proc%20Physiol%20Soc%2037PCB120 
Citation:  Zhang J, Shang L and Ma A (2016) CFTR Potentiator PG-01 and Corrector KM-11060 can 
rescue hERG mutations trafficking [Proceedings abstract]. The Physiological Society Proceedings 
Abstracts. Cellular signalling abstracts. 37, PCB120. 
Copyright statement:  © 2016 The Authors. Published by the Physiological Society. Reproduced 
in accordance with the publisher's self-archiving policy. 
CONTROL ID: 2531274
TITLE: CFTR Potentiator PG-01 and Corrector KM-11060 can rescue hERG mutations trafficking
PRESENTATION TYPE: General Communication
CURRENT SPECIAL INTEREST GROUP: Cellular Signalling.
Theme GC: Epithelia & Membrane Transport
AUTHORS (FIRST NAME, LAST NAME): Jinwen Zhang1, Lijun Shang2, Aiqun Ma1
INSTITUTIONS (ALL): 
1. Department of Cardiovascular Medicine, First Affiliated Hospital of Xi’an Jiao Tong University, Xi'an, China.
2. School of Medical Sciences, University of Bradford, Bradford, United Kingdom.
ABSTRACT BODY: 
Abstract Body : Type II congenitalLong QT syndrome (LQT2) is due to genetic mutations in hERG channel. Genetic or
pharmacological factors could potentially affect hERG channel biogenesis and contributes to LQTS, for example,
disease mutations G601S and T473P result in hERG trafficking deficiency [1,2]. Various rescue strategies for hERG
dysfuction are being developed. Some correctors for CFTR channel have been reported to act indirectly on
proteostasis pathways to promote folding and correction on hERG trafficking deficiency [3]. In this study, we tested the
hypothesis that the CFTR corrector KM-11060 and the potentiator PG-01 may correct hERG mutation trafficking
diseases.
 
We use HEK293 cell line expressing a well-studied trafficking disease mutation G601S-hERG channel [4]. We treated
cells with CFTR potentiator PG-01and corrector KM-11060, which function through different cellular mechanisms, and
assessed whether correction occurred via immunoblotting. Whole cell proteins from HEK 293 cells expressing hERG
channels were used for analysis [5]. Proteins were separated on 8% SDS-polyacrylamide electrophoresis gels for 1
hour, transferred onto PVDF membrane, and blocked for 1 h with 5% nonfat milk. The blots were incubated with the
primary antibody (Santa Cruz Biotechnology) for 12-16 h at 4C temperature and then incubated with a donkey anti-
goat horseradish peroxidase-conjugated secondary antibody( Santa Cruz Biotechnology). Actin expression was used
for loading controls. The blots were visualized using the ECL detection kit (Genshare).Results were deemed
significantly different from controls by a one-way ANOVA (p < 0.05).
 
Our results show that both KM-11060 (5, 10, 20uM) and PG-01(5, 15 uM) can correct G601S mutant alleles of hERG
protein trafficking (Fig 1, 2). KM-11060 (20uM) but not PG-01(15 uM) enhance protein expression of wild type hERG
channel (Fig 2). Further treatment on cells at low temperature with different drug concentration will be tested.
Functional studies are also needed to test whether the drugs can correct the function of hERG mutation channel.
These results could potentially provide novel insight into the correction mechanism of CFTR potentiator and also help
to develop new treatment for LQT2.
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Fig1. Representative blot showing WT-hERG or G601S-hERG vector transiently transfected HEK293 cell line before
and after KM11060(5,10uM) or PG-01(5uM) treatment. 135kDa and 155kDa indicate core and complex-glycosylated
hERG separately. Actin serves as a loading control;(A) WT-hERG express both core and complex-glycosylated
protein, while G601S-hERG only express 135kDa; KM11060(5,10uM) has no influence on WT-hERG protein
expression, while they and PG-01(5uM) can partly correct G601S-hERG which showing 155kDa protein after the
treatment;(B) the same with (A).
Fig2. Representative blot showing WT-hERG or G601S-hERG vector transiently transfected HEK293 cell line before
and after KM11060 (10,20uM) or PG-01(15uM) treatment. 135kDa and 155kDa indicate core and complex-
glycosylated hERG separately. KM11060 (10uM) has no influence on WT-hERG expression, but 20uM has increased
the expression of WT-hERG; PG-01(15uM) has not affect WT-hERG expression, while the same dosage can partly
correct G601S-hERG which present 155kDa after the treatment.
IMAGE CAPTION: Fig1. Representative blot showing WT-hERG or G601S-hERG vector transiently transfected
HEK293 cell line before and after KM11060(5,10uM) or PG-01(5uM) treatment. 135kDa and 155kDa indicate core and
complex-glycosylated hERG separately. Actin serves as a loading control;(A) WT-hERG express both core and
complex-glycosylated protein, while G601S-hERG only express 135kDa; KM11060(5,10uM) has no influence on WT-
hERG protein expression, while they and PG-01(5uM) can partly correct G601S-hERG which showing 155kDa protein
after the treatment;(B) the same with (A). Fig2. Representative blot showing WT-hERG or G601S-hERG vector
transiently transfected HEK293 cell line before and after KM11060 (10,20uM) or PG-01(15uM) treatment. 135kDa and
155kDa indicate core and complex-glycosylated hERG separately. KM11060 (10uM) has no influence on WT-hERG
expression, but 20uM has increased the expression of WT-hERG; PG-01(15uM) has not affect WT-hERG expression,
while the same dosage can partly correct G601S-hERG which present 155kDa after the treatment. 
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